Evidence map›Paper›PMID 41164877›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2026

Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis.

Murray D Polkinghorne, Ileana Badi, Andrea Baragetti, Jagat Chauhan, Cheng Xie, Elizabeth Wahome, Ioannis Akoumianakis, Daniel Foran, Parijat Patel, Edmarcia de Araujo and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Lipoprotein(a) in Essential Hypertension: Associations with Blood Pressure and Hypertension-Mediated Organ Damage.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
    Observational
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Murray D PolkinghorneDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.ORCID 0000-0002-8686-6192
Ileana BadiDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.ORCID 0000-0001-7581-2108
Andrea BaragettiDepartment of Excellence of Pharmacological and Biomolecular Sciences, University of Milan, Italy (A.B., G.D.N.).ORCID 0000-0002-6216-1999
Jagat ChauhanDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.ORCID 0000-0003-4210-6260
Cheng XieDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.
Elizabeth WahomeDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.ORCID 0000-0001-8386-7555
Ioannis AkoumianakisDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.ORCID 0000-0002-4674-0210
Daniel ForanDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.
Parijat PatelDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.
Edmarcia de AraujoDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.ORCID 0009-0006-8343-5588
Christos P KotanidisDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.
George KrasopoulosJohn Radcliffe Hospital, Oxford University Hospitals, United Kingdom (G.K, R.S., V.S., A.K., N.W., P.S.).ORCID 0000-0001-9334-9604
Rana SayeedJohn Radcliffe Hospital, Oxford University Hospitals, United Kingdom (G.K, R.S., V.S., A.K., N.W., P.S.).ORCID 0000-0002-2887-1874
Vivek SrivastavaJohn Radcliffe Hospital, Oxford University Hospitals, United Kingdom (G.K, R.S., V.S., A.K., N.W., P.S.).
Antonios KourliourosJohn Radcliffe Hospital, Oxford University Hospitals, United Kingdom (G.K, R.S., V.S., A.K., N.W., P.S.).
Nicholas WalcotJohn Radcliffe Hospital, Oxford University Hospitals, United Kingdom (G.K, R.S., V.S., A.K., N.W., P.S.).ORCID 0000-0002-2583-6467
Priya SastryJohn Radcliffe Hospital, Oxford University Hospitals, United Kingdom (G.K, R.S., V.S., A.K., N.W., P.S.).
Tomasz GuzikCentre for Cardiovascular Sciences, The University of Edinburgh, United Kingdom (T.G.).ORCID 0000-0002-5039-7849
Keith M ChannonDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.ORCID 0000-0002-1043-4342
Giuseppe D NorataDepartment of Excellence of Pharmacological and Biomolecular Sciences, University of Milan, Italy (A.B., G.D.N.).ORCID 0000-0002-6081-1257
Charalambos AntoniadesDivision of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.ORCID 0000-0002-6983-5423

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLp(a) (lipoprotein[a]) is associated with cardiovascular disease, but neither the causal nature nor the underlying mechanisms are fully documented. This study investigated whether Lp(a) triggers atherogenesis by dysregulating vascular redox-sensitive inflammatory state.

methodsPlasma Lp(a) was measured in 1027 patients with advanced coronary artery disease undergoing cardiac surgery. These patients were genotyped, and a modified

resultsIncreased plasma Lp(a) (

conclusionsThis study demonstrates for the first time that a genetically determined increase in plasma Lp(a) results in dysregulated vascular redox/nitrosative signaling in patients with atherosclerosis.

Indexed as

Coronary Artery DiseaseLipoprotein(a)AgedBiomarkersFemaleHumansMaleMiddle AgedNADPH OxidasesNitric Oxide Synthase Type IIIOxidation-ReductionOxidative StressSuperoxidesBiomarkersLipoprotein(a)LPA protein, humanNADPH OxidasesNitric Oxide Synthase Type IIINOS3 protein, humanSuperoxidesatherosclerosiscoronary artery diseaseinflammationlipoprotein(a)risk factors

Identifiers

PMID41164877
PMCPMC12721630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.